HRP20211450T1 - Dugodjelujuće formulacije - Google Patents
Dugodjelujuće formulacije Download PDFInfo
- Publication number
- HRP20211450T1 HRP20211450T1 HRP20211450TT HRP20211450T HRP20211450T1 HR P20211450 T1 HRP20211450 T1 HR P20211450T1 HR P20211450T T HRP20211450T T HR P20211450TT HR P20211450 T HRP20211450 T HR P20211450T HR P20211450 T1 HRP20211450 T1 HR P20211450T1
- Authority
- HR
- Croatia
- Prior art keywords
- preparation
- bedaquiline
- months
- pharmaceutically acceptable
- range
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims 10
- QUIJNHUBAXPXFS-XLJNKUFUSA-N bedaquiline Chemical compound C1([C@H](C2=CC3=CC(Br)=CC=C3N=C2OC)[C@@](O)(CCN(C)C)C=2C3=CC=CC=C3C=CC=2)=CC=CC=C1 QUIJNHUBAXPXFS-XLJNKUFUSA-N 0.000 claims 8
- 229960000508 bedaquiline Drugs 0.000 claims 8
- 239000000825 pharmaceutical preparation Substances 0.000 claims 6
- 239000011859 microparticle Substances 0.000 claims 4
- 239000002105 nanoparticle Substances 0.000 claims 4
- 239000003607 modifier Substances 0.000 claims 3
- 239000002245 particle Substances 0.000 claims 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims 2
- 229930195729 fatty acid Natural products 0.000 claims 2
- 239000000194 fatty acid Substances 0.000 claims 2
- 238000010255 intramuscular injection Methods 0.000 claims 2
- 239000007927 intramuscular injection Substances 0.000 claims 2
- 229920001983 poloxamer Polymers 0.000 claims 2
- 238000010254 subcutaneous injection Methods 0.000 claims 2
- 239000007929 subcutaneous injection Substances 0.000 claims 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 1
- 206010062207 Mycobacterial infection Diseases 0.000 claims 1
- 241000186362 Mycobacterium leprae Species 0.000 claims 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical group C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 229920001214 Polysorbate 60 Polymers 0.000 claims 1
- 229930003427 Vitamin E Natural products 0.000 claims 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims 1
- 239000008365 aqueous carrier Substances 0.000 claims 1
- 239000006172 buffering agent Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 235000013601 eggs Nutrition 0.000 claims 1
- -1 fatty acid ester Chemical class 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 238000011866 long-term treatment Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 208000027531 mycobacterial infectious disease Diseases 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- 229960000502 poloxamer Drugs 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229920000136 polysorbate Polymers 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- 229940046009 vitamin E Drugs 0.000 claims 1
- 235000019165 vitamin E Nutrition 0.000 claims 1
- 239000011709 vitamin E Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 239000008215 water for injection Substances 0.000 claims 1
- 239000000080 wetting agent Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17181354 | 2017-07-14 | ||
| EP18167463 | 2018-04-16 | ||
| PCT/EP2018/069066 WO2019012100A1 (en) | 2017-07-14 | 2018-07-13 | EXTENDED ACTION FORMULATIONS |
| EP18739856.5A EP3651736B1 (en) | 2017-07-14 | 2018-07-13 | Long-acting formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211450T1 true HRP20211450T1 (hr) | 2022-01-07 |
Family
ID=62874924
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211450TT HRP20211450T1 (hr) | 2017-07-14 | 2018-07-13 | Dugodjelujuće formulacije |
| HRP20240058TT HRP20240058T1 (hr) | 2017-07-14 | 2018-07-13 | Formulacije bedakvilina s dugotrajnim djelovanjem |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240058TT HRP20240058T1 (hr) | 2017-07-14 | 2018-07-13 | Formulacije bedakvilina s dugotrajnim djelovanjem |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US11141384B2 (https=) |
| EP (3) | EP3651736B1 (https=) |
| JP (3) | JP7102500B2 (https=) |
| KR (2) | KR20240108542A (https=) |
| CN (2) | CN110869004B (https=) |
| AU (1) | AU2018298855B2 (https=) |
| BR (1) | BR112020000687A2 (https=) |
| CO (1) | CO2020000328A2 (https=) |
| CY (1) | CY1124782T1 (https=) |
| DK (2) | DK3651736T3 (https=) |
| ES (2) | ES2891976T3 (https=) |
| FI (1) | FI3943070T3 (https=) |
| HR (2) | HRP20211450T1 (https=) |
| HU (2) | HUE064651T2 (https=) |
| JO (1) | JOP20200004B1 (https=) |
| LT (2) | LT3651736T (https=) |
| MD (1) | MD3651736T2 (https=) |
| MX (1) | MX393782B (https=) |
| PE (1) | PE20200336A1 (https=) |
| PH (1) | PH12020500076A1 (https=) |
| PL (2) | PL3651736T3 (https=) |
| RS (2) | RS62362B1 (https=) |
| SA (1) | SA520410975B1 (https=) |
| SI (2) | SI3943070T1 (https=) |
| SM (2) | SMT202400033T1 (https=) |
| UA (1) | UA126403C2 (https=) |
| WO (1) | WO2019012100A1 (https=) |
| ZA (1) | ZA202000215B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3943070T1 (sl) | 2017-07-14 | 2024-03-29 | Janssen Pharmaceutica Nv, | Dolgo delujoče formulacije bedakilina |
| US20220023282A1 (en) * | 2018-12-13 | 2022-01-27 | Mannkind Corporation | Compositions of Bedaquiline, Combinations Comprising Them, Processes for Their Preparation, Uses and Methods of Treatment Comprising Them |
| MX2023000439A (es) * | 2020-07-09 | 2023-02-09 | Janssen Pharmaceutica Nv | Formulaciones a largo plazo. |
| JP2023532981A (ja) * | 2020-07-09 | 2023-08-01 | ヤンセン ファーマシューティカ エヌ．ベー． | 長時間作用型配合物 |
| CN115776882A (zh) * | 2020-07-09 | 2023-03-10 | 詹森药业有限公司 | 长效配制品 |
| KR20230107275A (ko) * | 2020-11-12 | 2023-07-14 | 얀센 파마슈티카 엔.브이. | 비결핵성 마이코박테리아 질환의 치료에서 베다퀼린, 에탐부톨 및 마크롤라이드의 조합물 |
| US11793808B2 (en) | 2021-02-22 | 2023-10-24 | Mannkind Corp. | Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them |
| CN119968203A (zh) | 2022-09-28 | 2025-05-09 | 詹森药业有限公司 | 长效配制品 |
| WO2024068693A1 (en) | 2022-09-28 | 2024-04-04 | Janssen Pharmaceutica Nv | Long-acting formulations |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US5346702A (en) | 1992-12-04 | 1994-09-13 | Sterling Winthrop Inc. | Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization |
| US5352459A (en) | 1992-12-16 | 1994-10-04 | Sterling Winthrop Inc. | Use of purified surface modifiers to prevent particle aggregation during sterilization |
| US6495534B2 (en) | 2000-05-15 | 2002-12-17 | Pharmacia & Upjohn Spa | Stabilized aqueous suspensions for parenteral use |
| ATE463482T1 (de) | 2002-07-25 | 2010-04-15 | Janssen Pharmaceutica Nv | Chinolinderivate und deren verwendung als mycobakterielle inhibitoren |
| EE05394B1 (et) | 2004-12-24 | 2011-04-15 | Janssen Pharmaceutica N.V. | Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis |
| SI1888604T1 (sl) | 2005-05-25 | 2012-08-31 | Janssen Pharmaceutica Nv | Postopek priprave (alfa s, beta r)-6-bromo-alfa-(2-(dimetilamino) etil)2-metoksi-alfa-1-naftalenil-beta-fenil-3-kinolinetanola |
| EP2040671B1 (en) * | 2006-06-23 | 2018-01-24 | Janssen Sciences Ireland UC | Aqueous suspensions of tmc278 |
| UA97813C2 (uk) | 2006-12-05 | 2012-03-26 | Янссен Фармацевтика Н.В. | Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу |
| TW201023912A (en) | 2008-12-05 | 2010-07-01 | Alcon Res Ltd | Pharmaceutical suspension |
| US9421194B2 (en) | 2010-04-05 | 2016-08-23 | Rutgers, The State University Of New Jersey | Lung targeting dual drug delivery system |
| TWI577377B (zh) | 2010-09-16 | 2017-04-11 | Ｖｉｉｖ醫療保健公司 | 醫藥組合物 |
| PL2696848T3 (pl) | 2011-04-15 | 2020-12-28 | Janssen Pharmaceutica N.V. | Liofilizowane nanozawiesiny leków |
| CA2956550A1 (en) | 2014-08-08 | 2016-02-11 | Pharmacyclics Llc | Bruton's tyrosine kinase inhibitor combinations and uses thereof |
| IL310920A (en) | 2015-01-27 | 2024-04-01 | Janssen Pharmaceutica Nv | Dispersible compositions |
| US10653679B2 (en) * | 2015-05-04 | 2020-05-19 | Board Of Trustees Of Michigan State University | Compositions and methods for inhibiting bacterial growth |
| HK1254620A1 (zh) | 2015-10-14 | 2019-07-26 | 结核病药物开发全球联盟公司 | 联合抗菌组合物以及短疗程抗菌方案 |
| CN108349898B (zh) * | 2015-10-20 | 2021-03-23 | 浙江海正药业股份有限公司 | 富马酸贝达喹啉的晶型及其制备方法 |
| EP3634583A4 (en) | 2017-06-06 | 2021-03-03 | Merck Sharp & Dohme Corp. | LONG-LASTING EFFECT IMPLANT FOR THE TREATMENT OF INFECTIOUS DISEASES |
| SI3943070T1 (sl) | 2017-07-14 | 2024-03-29 | Janssen Pharmaceutica Nv, | Dolgo delujoče formulacije bedakilina |
| JP2023532981A (ja) | 2020-07-09 | 2023-08-01 | ヤンセン ファーマシューティカ エヌ．ベー． | 長時間作用型配合物 |
| MX2023000439A (es) | 2020-07-09 | 2023-02-09 | Janssen Pharmaceutica Nv | Formulaciones a largo plazo. |
| CN115776882A (zh) | 2020-07-09 | 2023-03-10 | 詹森药业有限公司 | 长效配制品 |
-
2018
- 2018-07-13 SI SI201930692T patent/SI3943070T1/sl unknown
- 2018-07-13 KR KR1020247021329A patent/KR20240108542A/ko active Pending
- 2018-07-13 EP EP18739856.5A patent/EP3651736B1/en active Active
- 2018-07-13 RS RS20211178A patent/RS62362B1/sr unknown
- 2018-07-13 SM SM20240033T patent/SMT202400033T1/it unknown
- 2018-07-13 MX MX2020000461A patent/MX393782B/es unknown
- 2018-07-13 MD MDE20200530T patent/MD3651736T2/ro not_active IP Right Cessation
- 2018-07-13 DK DK18739856.5T patent/DK3651736T3/da active
- 2018-07-13 ES ES18739856T patent/ES2891976T3/es active Active
- 2018-07-13 PL PL18739856T patent/PL3651736T3/pl unknown
- 2018-07-13 AU AU2018298855A patent/AU2018298855B2/en active Active
- 2018-07-13 SI SI201830409T patent/SI3651736T1/sl unknown
- 2018-07-13 ES ES21178526T patent/ES2970801T3/es active Active
- 2018-07-13 RS RS20240102A patent/RS65207B1/sr unknown
- 2018-07-13 US US16/630,676 patent/US11141384B2/en active Active
- 2018-07-13 FI FIEP21178526.6T patent/FI3943070T3/fi active
- 2018-07-13 CN CN201880046696.8A patent/CN110869004B/zh active Active
- 2018-07-13 HU HUE21178526A patent/HUE064651T2/hu unknown
- 2018-07-13 KR KR1020207003364A patent/KR102679979B1/ko active Active
- 2018-07-13 HR HRP20211450TT patent/HRP20211450T1/hr unknown
- 2018-07-13 DK DK21178526.6T patent/DK3943070T3/da active
- 2018-07-13 JO JOP/2020/0004A patent/JOP20200004B1/ar active
- 2018-07-13 LT LTEPPCT/EP2018/069066T patent/LT3651736T/lt unknown
- 2018-07-13 EP EP21178526.6A patent/EP3943070B1/en active Active
- 2018-07-13 UA UAA202000901A patent/UA126403C2/uk unknown
- 2018-07-13 CN CN202210671005.1A patent/CN115252548A/zh active Pending
- 2018-07-13 PL PL21178526.6T patent/PL3943070T3/pl unknown
- 2018-07-13 WO PCT/EP2018/069066 patent/WO2019012100A1/en not_active Ceased
- 2018-07-13 HR HRP20240058TT patent/HRP20240058T1/hr unknown
- 2018-07-13 PE PE2020000033A patent/PE20200336A1/es unknown
- 2018-07-13 HU HUE18739856A patent/HUE055762T2/hu unknown
- 2018-07-13 BR BR112020000687-4A patent/BR112020000687A2/pt unknown
- 2018-07-13 LT LTEP21178526.6T patent/LT3943070T/lt unknown
- 2018-07-13 JP JP2020501137A patent/JP7102500B2/ja active Active
- 2018-07-13 SM SM20210557T patent/SMT202100557T1/it unknown
- 2018-07-13 EP EP23206129.1A patent/EP4356968A3/en active Pending
-
2020
- 2020-01-06 SA SA520410975A patent/SA520410975B1/ar unknown
- 2020-01-09 PH PH12020500076A patent/PH12020500076A1/en unknown
- 2020-01-13 ZA ZA2020/00215A patent/ZA202000215B/en unknown
- 2020-01-14 CO CONC2020/0000328A patent/CO2020000328A2/es unknown
-
2021
- 2021-09-08 US US17/469,021 patent/US12171887B2/en active Active
- 2021-09-23 CY CY20211100837T patent/CY1124782T1/el unknown
-
2022
- 2022-07-06 JP JP2022108846A patent/JP7441276B2/ja active Active
-
2023
- 2023-12-22 JP JP2023216574A patent/JP7620692B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211450T1 (hr) | Dugodjelujuće formulacije | |
| Espinoza et al. | Formulation strategies to improve nose-to-brain delivery of donepezil | |
| HRP20241265T3 (hr) | Vodene suspenzije tmc278 | |
| Abdelkader et al. | Recent advances in non-ionic surfactant vesicles (niosomes): self-assembly, fabrication, characterization, drug delivery applications and limitations | |
| Hussain et al. | Elastic liposomes as novel carriers: recent advances in drug delivery | |
| Doktorovova et al. | Preclinical safety of solid lipid nanoparticles and nanostructured lipid carriers: Current evidence from in vitro and in vivo evaluation | |
| Kim et al. | Lyotropic liquid crystal systems in drug delivery: a review | |
| US9526787B2 (en) | Sustained-release lipid pre-concentrate of pharmacologically active substance and pharmaceutical composition comprising the same | |
| ES2369244T3 (es) | Sistemas estables de nanocápsulas para la administración de moléculas activas. | |
| JP2020526538A5 (https=) | ||
| ES2539861T3 (es) | Formulaciones en emulsión de clevidipina que contienen agentes antimicrobianos | |
| JP6537980B2 (ja) | 脂質化合物、トリグリセリドおよび界面活性剤を含む組成物、ならびにその使用方法 | |
| JP2017533243A5 (https=) | ||
| US20210346396A1 (en) | Fulvestrant formulations and methods of their use | |
| JP2015520235A5 (https=) | ||
| TW201111382A (en) | Intravenous formulations of neurokinin-1 antagonists | |
| JP2011510001A (ja) | イミキモド製剤 | |
| AR109757A1 (es) | Nanopartículas lipídicas modificadas con apo-e para la administración de fármacos a tejidos específicos y métodos terapéuticos | |
| JP2016504352A (ja) | アニオン性薬理学的活性物質の徐放性脂質初期製剤およびこれを含む薬剤学的組成物 | |
| ES2481940B1 (es) | Nanocápsulas de protamina | |
| JP2020522502A (ja) | 沈殿抵抗性低分子薬物製剤 | |
| illastria Rosalina et al. | Novasome: combining ufasome and niosome for excellent vesicular drug delivery system | |
| US20120308663A1 (en) | Lipid nanocapsules, method for preparing same and use thereof as a drug | |
| RU2017110076A (ru) | Фармацевтическая композиция и способы | |
| JP2017530149A (ja) | 低用量経口イソトレチノイン医薬組成物 |